HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Online-Only Appendix All Versions of this Article: dc08-0283v1 31/8/1479    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Google Scholar Articles by Fonseca, V. A. Articles by Jones, M. R. PubMed PubMed Citation Articles by Fonseca, V. A. Articles by Jones, M. R. Social Bookmarking                What's this?

Colesevelam HCl Improves Glycemic Control and Reduces LDL Cholesterol in Patients With Inadequately Controlled Type 2 Diabetes on Sulfonylurea-Based Therapy

¹ Tulane University Health Sciences Center, New Orleans, Louisiana
² Dallas Diabetes and Endocrine Center, Dallas, Texas
³ Daiichi Sankyo Pharma Development, Edison, New Jersey
⁴ Daiichi Sankyo, Inc., Parsippany, New Jersey

Corresponding author: Vivian Fonseca, vfonseca{at}tulane.edu

OBJECTIVE—Hyperglycemia is a risk factor for microvascular complications and may increase the risk of cardiovascular disease in patients with type 2 diabetes. This study tested the LDL cholesterol–lowering agent colesevelam HCl (colesevelam) as a potential novel treatment for improving glycemic control in patients with type 2 diabetes on sulfonylurea-based therapy.

RESEARCH DESIGN AND METHODS—A 26-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter study was carried out between August 2004 and August 2006 to evaluate the efficacy and safety of colesevelam for reducing A1C in adults with type 2 diabetes whose glycemic control was inadequate (A1C 7.5–9.5%) with existing sulfonylurea monotherapy or sulfonylurea in combination with additional oral antidiabetes agents. In total, 461 patients were randomized (230 given colesevelam 3.75 g/day and 231 given placebo). The primary efficacy measurement was mean placebo-corrected change in A1C from baseline to week 26 in the intent-to-treat population (last observation carried forward).

RESULTS—The least squares (LS) mean change in A1C from baseline to week 26 was –0.32% in the colesevelam group and +0.23% in the placebo group, resulting in a treatment difference of –0.54% (P < 0.001). The LS mean percent change in LDL cholesterol from baseline to week 26 was –16.1% in the colesevelam group and +0.6% in the placebo group, resulting in a treatment difference of –16.7% (P < 0.001). Furthermore, significant reductions in fasting plasma glucose, fructosamine, total cholesterol, non–HDL cholesterol, and apolipoprotein B were demonstrated in the colesevelam relative to placebo group at week 26.

CONCLUSIONS—Colesevelam improved glycemic control and reduced LDL cholesterol levels in patients with type 2 diabetes receiving sulfonylurea-based therapy.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				Z. T. Bloomgarden American College of Endocrinology Pre-Diabetes Consensus Conference: Part Two Diabetes Care, November 1, 2008; 31(11): 2222 - 2229. [Full Text] [PDF]